The Gene-Editing News That Sent Beleaguered Intellia Therapeutics Stock Up 10%Investors Business Daily • 01/27/26
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving AverageZacks Investment Research • 01/14/26
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/07/26
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 11/21/25
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?Zacks Investment Research • 11/14/25
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with CardiomyopathyGlobeNewsWire • 11/10/25
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary AngioedemaGlobeNewsWire • 11/08/25
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline TroubleZacks Investment Research • 11/07/25
Intellia Therapeutics Crashes After A Patient In Its Pivotal Study DiesInvestors Business Daily • 11/07/25
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall StreetThe Motley Fool • 11/07/25
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/06/25
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%The Motley Fool • 11/02/25
Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z TranscriptSeeking Alpha • 10/27/25
Intellia pauses late-stage trials of gene-editing treatment after serious liver eventReuters • 10/27/25